지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.1
- 수록면
- 26 - 33 (8page)
이용수
초록· 키워드
오류제보하기
The identification of driver mutations in Janus kinase (JAK ) 2, calreticulin (CALR ), and myeloproliferative leukemia (MPL) has contributed to a better understanding of disease pathogenesis by highlighting the importance of JAK signal transducer and activator of transcription (STAT) signaling in classical myeloproliferative neoplasms (MPNs). This has led to the therapeutic use of novel targeted treatments, such as JAK2 inhibitors. More recently, with the development of next-generation sequencing, additional somatic mutations, which are not restricted to MPNs, have been elucidated. Treatment decisions for MPN patients are influenced by the MPN subtype, symptom burden, and risk classification. Although prevention of vascular events is the main objective of therapy for essential thrombocythemia (ET) and polycythemia vera (PV) patients, disease-modifying drugs are needed to eradicate clonal hematopoiesis and prevent progression to more aggressive myeloid neoplasms. JAK inhibitors are a valuable therapeutic strategy for patients with myelofibrosis (MF) who have splenomegaly and/or disease-related symptoms, but intolerance, refractory, resistance, and disease progression still present challenges. Currently, allogeneic stem cell transplantation remains the only curative treatment for MF, but it is typically limited by age-related comorbidities and high treatment- related mortality. Therefore, a better understanding of the molecular pathogenesis and potential new therapies with the aim of modifying the natural history of the disease is important. In this article, I review the current understanding of the molecular basis of MPNs and clinical studies on potential disease-modifying agents.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Disease modifying agents of myeloproliferative neoplasms: a review
Blood Research
2021 .04
-
Novel therapeutic strategies for essential thrombocythemia/polycythemia vera
Blood Research
2023 .04
-
Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms
Annals of Laboratory Medicine
2015 .01
-
Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms
Annals of Laboratory Medicine
2018 .01
-
JAK2 V617F-Positive Acute Myeloid Leukemia: Clinicopathological Features of Two Cases
Laboratory Medicine Online
2022 .01
-
골수증식 종양의 2017년 WHO 진단기준 주요 변경 사항의 이해
대한내과학회지
2018 .01
-
A t(8;9)(p22;p24)/PCM1-JAK2 Translocation in a Patient With Myeloproliferative Neoplasm and Myeloid Sarcoma: First Report in Korea
Annals of Laboratory Medicine
2016 .01
-
골수증식종양 환자에서 MPL W515 돌연변이 빈도와 임상혈액학적 특징
Laboratory Medicine Online
2015 .01
-
Novel therapeutics for myelofibrosis
Blood Research
2023 .04
-
A Rare Case of Essential Thrombocythemia with Coexisting JAK2 and MPL Driver Mutations
Journal of Korean Medical Science
2020 .01
-
Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations
Annals of Laboratory Medicine
2017 .01
-
Prognostication in myeloproliferative neoplasms, including mutational abnormalities
Blood Research
2023 .04
-
골수증식종양 진단의 발전
대한내과학회지
2016 .01
-
Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
Blood Research
2021 .12
-
골수섬유증 치료의 발전
대한내과학회지
2016 .01
-
The First Case Report of JAK2–BCR–PPP1R32 Fusion Genes Because of a Translocation (9;22;11)(p24;q11.2;q13) in a Patient With Myeloproliferative Neoplasm
Annals of Laboratory Medicine
2023 .05
-
Clinical significance of myeloproliferative neoplasms with JAK2V617F mutations and major BCR-ABL1 translocations: a literature review with case presentation
Blood Research
2020 .01
-
GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms
Annals of Laboratory Medicine
2018 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0